GSK to Acquire RAPT Therapeutics for $2.2 Billion in Cash Tender Offer at $58.00 Per Share

summarizeSummary

RAPT Therapeutics has entered into a definitive merger agreement to be acquired by GlaxoSmithKline LLC for $58.00 per share in cash, valuing the company at approximately $2.2 billion. The acquisition, which includes the promising anti-IgE antibody ozureprubart, will proceed via a cash tender offer.

check_boxKey Events

• Definitive Merger Agreement

  RAPT Therapeutics, Inc. has entered into an Agreement and Plan of Merger with GlaxoSmithKline LLC (GSK) and its subsidiary, Redrose Acquisition Co., for a full acquisition.

• Acquisition Price and Value

  GSK will acquire all outstanding shares of RAPT common stock for $58.00 per share in cash, representing an estimated aggregate equity value of $2.2 billion. This is a significant premium over the current stock price of $57.40 and the 52-week high of $42.39.

• Strategic Asset Acquisition

  The acquisition includes ozureprubart, RAPT's long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in Phase IIb clinical development for prophylactic protection against food allergens. GSK views this as a potential best-in-class treatment.

• Deal Structure and Timeline

  The transaction will be executed through a cash tender offer, expected to commence within 10 business days, followed by a second-step merger. The transaction is anticipated to close in the first quarter of 2026.

auto_awesomeAnalysis

This 8-K filing announces a definitive agreement for GlaxoSmithKline LLC (GSK) to acquire RAPT Therapeutics, Inc. for an estimated aggregate equity value of $2.2 billion. The offer price of $58.00 per share represents a significant premium over the current trading price of $57.40 and the company's 52-week high of $42.39. This acquisition is a thesis-altering event for RAPT Therapeutics, providing a clear exit for shareholders at a substantial valuation. The deal is structured as a cash tender offer followed by a second-step merger, which simplifies the process for shareholders. GSK highlights RAPT's lead asset, ozureprubart, an anti-IgE antibody for food allergies, as a key strategic driver, complementing GSK's existing Respiratory, Immunology & Inflammation pipeline. Investors should monitor the tender offer process and regulatory approvals, particularly under the HSR Act, although the reverse termination fee indicates GSK's commitment to closing the deal.